JP7711959B2 - 改変型アデノウイルスヘキソンタンパク質を有するアデノウイルス - Google Patents
改変型アデノウイルスヘキソンタンパク質を有するアデノウイルスInfo
- Publication number
- JP7711959B2 JP7711959B2 JP2022523434A JP2022523434A JP7711959B2 JP 7711959 B2 JP7711959 B2 JP 7711959B2 JP 2022523434 A JP2022523434 A JP 2022523434A JP 2022523434 A JP2022523434 A JP 2022523434A JP 7711959 B2 JP7711959 B2 JP 7711959B2
- Authority
- JP
- Japan
- Prior art keywords
- hadv5
- adenovirus
- modified
- mscs
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10345—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19204420.4A EP3812465A1 (en) | 2019-10-21 | 2019-10-21 | Adenovirus comprising a modified adenovirus hexon protein |
| EP19204420.4 | 2019-10-21 | ||
| PCT/EP2020/079494 WO2021078735A1 (en) | 2019-10-21 | 2020-10-20 | Adenovirus comprising a modified adenovirus hexon protein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022552870A JP2022552870A (ja) | 2022-12-20 |
| JP2022552870A5 JP2022552870A5 (cg-RX-API-DMAC7.html) | 2023-10-17 |
| JP7711959B2 true JP7711959B2 (ja) | 2025-07-23 |
Family
ID=68296308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022523434A Active JP7711959B2 (ja) | 2019-10-21 | 2020-10-20 | 改変型アデノウイルスヘキソンタンパク質を有するアデノウイルス |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12435112B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP3812465A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7711959B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3158189A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021078735A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024005211A1 (ja) * | 2022-06-27 | 2024-01-04 | 国立大学法人大阪大学 | ヘキソン改変型アデノウイルスベクター |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002525065A (ja) | 1998-09-11 | 2002-08-13 | ジェンベク、インコーポレイティッド | 選択的にターゲッティングされるアデノウイルス |
| JP2009535032A (ja) | 2006-04-28 | 2009-10-01 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 改変アデノウイルスヘキソンタンパク質およびその用途 |
| JP2015506704A (ja) | 2012-02-02 | 2015-03-05 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 腫瘍関連異種抗原を発現するアデノウイルス |
| JP2016521709A (ja) | 2013-06-05 | 2016-07-25 | ベリカム ファーマシューティカルズ, インコーポレイテッド | カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法 |
| JP2017518765A (ja) | 2014-05-14 | 2017-07-13 | ザ ユニバーシティー コート オブ ザ ユニバーシティー オブ アバーディーンThe University Court Of The University Of Aberdeen | 膵島細胞入手方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2236912C (en) * | 1995-11-28 | 2006-04-25 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
| US9017672B2 (en) * | 2012-05-11 | 2015-04-28 | Immunicum Aktiebolag | Hexon Tat-PTD modified adenovirus and uses thereof |
| ES2899913T3 (es) * | 2014-09-24 | 2022-03-15 | Salk Inst For Biological Studi | Virus tumorales oncolíticos y métodos de uso |
| EP3247807B1 (en) * | 2015-01-20 | 2020-12-16 | Adcure Biotechnologies, LLC. | Detargeted adenovirus variants and related methods |
| GB201802539D0 (en) * | 2018-02-16 | 2018-04-04 | Univ College Cardiff Consultants Ltd | Modified adenoviruses |
-
2019
- 2019-10-21 EP EP19204420.4A patent/EP3812465A1/en not_active Withdrawn
-
2020
- 2020-10-20 US US17/769,689 patent/US12435112B2/en active Active
- 2020-10-20 EP EP20790327.9A patent/EP4048798B1/en active Active
- 2020-10-20 EP EP24177872.9A patent/EP4407025A3/en not_active Withdrawn
- 2020-10-20 CA CA3158189A patent/CA3158189A1/en active Pending
- 2020-10-20 WO PCT/EP2020/079494 patent/WO2021078735A1/en not_active Ceased
- 2020-10-20 JP JP2022523434A patent/JP7711959B2/ja active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002525065A (ja) | 1998-09-11 | 2002-08-13 | ジェンベク、インコーポレイティッド | 選択的にターゲッティングされるアデノウイルス |
| JP2009535032A (ja) | 2006-04-28 | 2009-10-01 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 改変アデノウイルスヘキソンタンパク質およびその用途 |
| JP2015506704A (ja) | 2012-02-02 | 2015-03-05 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 腫瘍関連異種抗原を発現するアデノウイルス |
| JP2016521709A (ja) | 2013-06-05 | 2016-07-25 | ベリカム ファーマシューティカルズ, インコーポレイテッド | カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法 |
| JP2017518765A (ja) | 2014-05-14 | 2017-07-13 | ザ ユニバーシティー コート オブ ザ ユニバーシティー オブ アバーディーンThe University Court Of The University Of Aberdeen | 膵島細胞入手方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4048798A1 (en) | 2022-08-31 |
| EP3812465A1 (en) | 2021-04-28 |
| WO2021078735A1 (en) | 2021-04-29 |
| US12435112B2 (en) | 2025-10-07 |
| CA3158189A1 (en) | 2021-04-29 |
| EP4407025A3 (en) | 2025-01-15 |
| US20220380411A1 (en) | 2022-12-01 |
| EP4048798C0 (en) | 2024-06-26 |
| JP2022552870A (ja) | 2022-12-20 |
| EP4048798B1 (en) | 2024-06-26 |
| EP4407025A2 (en) | 2024-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6375273B2 (ja) | 腫瘍選択的e1aおよびe1b変異体 | |
| EP2871239B1 (en) | Cell capable of producing adeno-associated virus vector | |
| JP3565859B2 (ja) | 改良されたアデノウイルスおよびその使用法 | |
| KR20220155981A (ko) | 미성숙 종결 코돈-매개 장애를 치료하기 위한 방법 및 조성물 | |
| JP6388593B2 (ja) | E1bタンパク質の156rスプライシングアイソフォームの割合を増加させた腫瘍溶解性アデノウイルス | |
| JP7558808B2 (ja) | 組換えアデノウイルスおよびこれを含む幹細胞 | |
| CN113227361B (zh) | 腺病毒和使用腺病毒的方法 | |
| CN111479582B (zh) | 免疫调节的复制高效的痘苗病毒株 | |
| JP4955397B2 (ja) | 腫瘍崩壊性のアデノウイルス | |
| Lundstrom | Application of viruses for gene therapy and vaccine development | |
| EP4048798B1 (en) | Adenovirus comprising a modified adenovirus hexon protein | |
| JP2004502426A (ja) | 平滑筋の発現を制御するキメラプロモーター | |
| JP7508109B2 (ja) | ヒト35型アデノウイルスを基盤とした腫瘍溶解性ウイルス | |
| JP7816735B2 (ja) | 腫瘍溶解性ウイルス及びそれを用いたがん治療 | |
| Thiaville et al. | Hope Unlocked: Gene Therapy with Viral Vectors and Gene Editing | |
| JP2010512760A (ja) | 組換えkhp53遺伝子のアデノウイルス組換え体及びその調製方法と用途 | |
| CN116769734A (zh) | 一种缺氧微环境响应溶瘤病毒株的构建及其应用 | |
| WO2026003069A1 (en) | Constructs and vectors for reprogramming cells to cdc1 cells, compositions and methods thereof | |
| TWI391486B (zh) | 新穎啟動子及包含其之病毒載體 | |
| HK40057763B (en) | Adenoviruses and methods for using adenoviruses | |
| Le Guiner et al. | Effective Limb Transduction and Phenotypic Correction after Injection of rAAV8-U7 snRNA in GRMD Dogs | |
| Panakanti | Therapeutic gene delivery to human pancreatic islets for treatment of diabetes and the effect of TFO on liver fibrosis induced by bile duct ligation | |
| Kohn et al. | Gene therapy and viruses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231006 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231006 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240913 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241001 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241226 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250218 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250519 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250610 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250703 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7711959 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |